Towards MRI guided radiotherapy of renal cell carcinoma

Completed

• Conditions: kidney cancer; Renal cell carcinoma; 10038364; 10038430

• Registration Number: NL-OMON42445
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

- Patients with a solid lesion suspect for RCC or a cystic lesion Bosniak classification > IIF;
- * 18 years;
- Written informed consent.

Exclusion Criteria

- Fulfilling one of the exclusion criteria for MRI at 1.5T/3T according to the protocol of the department of Radiology, UMC Utrecht;
- Fulfilling the exclusion criteria for the Gadovist gadolinium (glomerular filtration rate (GFR) of < 30 mL/min/1.73m2) (see also 'MRI contra indicaties Gadolinium gebruik' - guidelines UMC Utrecht, versie 5; april 2015);
- Patients with a known Gadovist allergy;
- Metastatic (regional or distant) RCC;
- Bosniak classification * IIF.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To make MRI suitable for MR-guided (MR-linac) stereotactic radiotherapy for<br /><br>localized RCC. The current predicate MRI work includes MRI-sequence<br /><br>optimisation (to allow for MR-based delineation) and MR-guidance during<br /><br>treatment.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>